



#8/a
DMT
3303

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SPURLOCK, Michael E. *et al.*
Serial No. 09/932,888
Title: PORCINE LEPTIN PROTEIN, ANTISENSE AND ANTIBODY
Filing Date: August 20, 2001
Examiner: Christine J. Saoud
Art Unit: 1647

RECEIVED
FEB 21 2003
TECH CENTER 1600/2900

CERTIFICATION UNDER 37 CFR 1.8(a) and 1.10

I hereby certify that, on the date shown below, this correspondence is being:

Mailing

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 CFR 1.8(a)

37 CFR 1.10

☐ with sufficient postage as first class mail

☒ As "Express Mail Post Office to Addressee" Mailing Label No. EV048319235US

Transmission

☐ transmitted by facsimile to Fax No.: _____ addressed to Examiner _____ at the Patent and Trademark Office.

Date: February 14, 2003

Gu R. Huk

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Sequence Disclosures mailed December 17, 2002, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 29, lines 1-21 thru page 30, lines 1-3, and replace it with the following paragraph:

A porcine *ob* (*obese* gene) cDNA probe was amplified from adipose tissue mRNA using the reverse transcriptase-polymerase chain reaction (RT-PCR). First strand cDNA synthesis reactions were carried out using 1-2 µg of porcine adipose tissue total RNA, 150 pmol of random hexamer oligonucleotides, 500 nM dNTP, 200 U of Superscript II reverse transcriptase (LifeTechnologies, Inc., Bethesda, MD, USA) in 20 µl of the supplied buffer.